Ameriprise Financial Inc. Buys 44,052 Shares of AngioDynamics, Inc. (ANGO)

Ameriprise Financial Inc. lifted its stake in AngioDynamics, Inc. (NASDAQ:ANGO) by 7.2% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 658,773 shares of the medical instruments supplier’s stock after acquiring an additional 44,052 shares during the period. Ameriprise Financial Inc. owned 1.80% of AngioDynamics worth $10,679,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. State of Alaska Department of Revenue increased its position in AngioDynamics by 91.7% during the 2nd quarter. State of Alaska Department of Revenue now owns 6,768 shares of the medical instruments supplier’s stock valued at $109,000 after buying an additional 3,238 shares in the last quarter. Teachers Retirement System of The State of Kentucky increased its position in AngioDynamics by 77.5% during the 1st quarter. Teachers Retirement System of The State of Kentucky now owns 7,100 shares of the medical instruments supplier’s stock valued at $123,000 after buying an additional 3,100 shares in the last quarter. Municipal Employees Retirement System of Michigan increased its position in AngioDynamics by 3.0% during the 1st quarter. Municipal Employees Retirement System of Michigan now owns 7,200 shares of the medical instruments supplier’s stock valued at $125,000 after buying an additional 210 shares in the last quarter. Mason Street Advisors LLC increased its position in AngioDynamics by 8.5% during the 1st quarter. Mason Street Advisors LLC now owns 7,470 shares of the medical instruments supplier’s stock valued at $130,000 after buying an additional 584 shares in the last quarter. Finally, BlueCrest Capital Management Ltd acquired a new position in AngioDynamics during the 1st quarter valued at about $175,000. 95.42% of the stock is owned by hedge funds and other institutional investors.

Shares of AngioDynamics, Inc. (NASDAQ ANGO) opened at 16.57 on Thursday. The firm’s 50-day moving average price is $17.32 and its 200 day moving average price is $16.37. The stock has a market cap of $608.37 million, a P/E ratio of 167.37 and a beta of 1.12. AngioDynamics, Inc. has a 1-year low of $14.80 and a 1-year high of $18.85.

AngioDynamics (NASDAQ:ANGO) last posted its earnings results on Thursday, September 28th. The medical instruments supplier reported $0.12 EPS for the quarter, missing the Zacks’ consensus estimate of $0.16 by ($0.04). AngioDynamics had a return on equity of 4.83% and a net margin of 1.64%. The firm had revenue of $85.40 million for the quarter, compared to analyst estimates of $86.12 million. During the same quarter last year, the firm posted $0.17 EPS. The firm’s revenue for the quarter was down 3.1% on a year-over-year basis. On average, equities analysts expect that AngioDynamics, Inc. will post $0.66 earnings per share for the current fiscal year.

In other news, CEO James C. Clemmer bought 20,000 shares of the business’s stock in a transaction dated Thursday, July 20th. The shares were acquired at an average price of $15.64 per share, for a total transaction of $312,800.00. Following the completion of the transaction, the chief executive officer now owns 86,683 shares of the company’s stock, valued at $1,355,722.12. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO James C. Clemmer bought 5,000 shares of the business’s stock in a transaction dated Friday, July 21st. The shares were purchased at an average price of $15.79 per share, for a total transaction of $78,950.00. Following the transaction, the chief executive officer now directly owns 86,683 shares of the company’s stock, valued at approximately $1,368,724.57. The disclosure for this purchase can be found here. Insiders have bought 25,316 shares of company stock worth $396,806 in the last quarter. Insiders own 1.80% of the company’s stock.

Several brokerages recently issued reports on ANGO. Canaccord Genuity reaffirmed a “hold” rating and set a $17.00 target price on shares of AngioDynamics in a research report on Sunday. Zacks Investment Research raised AngioDynamics from a “hold” rating to a “buy” rating and set a $19.00 target price on the stock in a research report on Tuesday, October 3rd. KeyCorp reaffirmed a “hold” rating on shares of AngioDynamics in a research report on Friday, September 29th. BidaskClub raised AngioDynamics from a “sell” rating to a “hold” rating in a research report on Saturday, August 19th. Finally, Barclays PLC reduced their target price on AngioDynamics from $17.00 to $16.00 and set an “equal weight” rating on the stock in a research report on Wednesday, July 19th. Four equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The company has a consensus rating of “Hold” and a consensus target price of $18.60.

COPYRIGHT VIOLATION WARNING: “Ameriprise Financial Inc. Buys 44,052 Shares of AngioDynamics, Inc. (ANGO)” was originally posted by Markets Daily and is owned by of Markets Daily. If you are accessing this news story on another website, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The legal version of this news story can be viewed at https://www.themarketsdaily.com/2017/10/12/ameriprise-financial-inc-buys-44052-shares-of-angiodynamics-inc-ango.html.

AngioDynamics Profile

AngioDynamics, Inc designs, manufactures and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. The Company’s devices are used in minimally invasive, image-guided procedures.

Institutional Ownership by Quarter for AngioDynamics (NASDAQ:ANGO)

Receive News & Ratings for AngioDynamics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply